Mechanisms Underlying the Waning of Osteoanabolic Therapy Effects in Osteoporosis - PubMed
4 hours ago
- #Anabolic Therapy
- #Osteoporosis
- #Bone Formation
- Osteoanabolic therapies like PTH analogs (teriparatide, abaloparatide) and romosozumab initially stimulate bone formation but effects wane over time.
- The waning effect typically occurs within 12-18 months for PTH analogs and sooner for romosozumab.
- Possible mechanisms include receptor desensitization, depletion of bone-forming surfaces, downregulation of osteoblast progenitors, and upregulation of Wnt antagonists.
- Contrasting kinetics of teriparatide, abaloparatide, and romosozumab are influenced by their modes of action (remodeling vs. modeling-based formation).
- Strategies to extend anabolic effects include sequential/combination therapies and adjunctive mechanical loading.
- Understanding the attenuation of anabolic drug efficacy provides insights into bone biology and helps design better treatment regimens.